SURROZEN INC(NASDAQ:SRZN) stock News

SRZN Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Surrozen, Inc.

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conference

2 months ago - By: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conference

2 months ago - By: The Motley Fool

Surrozen Reports Q2 Profit on Gains

2 months ago - By: Surrozen, Inc.

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conference

a year ago - By: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conferences

a year ago - By: BusinessInsider

SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024

a year ago - By: InvestorPlace

SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024

a year ago - By: BusinessInsider

SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024

5 months ago - By: Zacks Investment Research

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

5 months ago - By: Surrozen, Inc.

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

5 months ago - By: Surrozen, Inc.

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Surrozen, Inc.

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

7 months ago - By: Surrozen, Inc.

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

a year ago - By: InvestorPlace

SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024

2 years ago - By: BusinessInsider

SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023

2 years ago - By: InvestorPlace

SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023

9 months ago - By: Benzinga - Mentions: WOR FHTX KSCP PHIN

This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

10 months ago - By: Benzinga - Mentions: CYCC AHG ONCO EYEN ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

10 months ago - By: Yahoo Finance - Mentions: RJF CHWY SQ JBHT

Block upgraded, Bumble downgraded: Wall Street's top analyst calls

a year ago - By: Surrozen, Inc.

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

a year ago - By: Surrozen, Inc.

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

a year ago - By: Surrozen, Inc.

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

2 years ago - By: BusinessInsider

SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023

2 years ago - By: InvestorPlace

SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023

2 years ago - By: BusinessInsider

SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023

a year ago - By: Surrozen, Inc.

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

a year ago - By: Surrozen, Inc.

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

a year ago - By: Surrozen, Inc.

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

a year ago - By: Surrozen, Inc.

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

a year ago - By: Surrozen, Inc.

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

2 years ago - By: InvestorPlace

SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023

a year ago - By: Surrozen, Inc.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

2 years ago - By: Surrozen, Inc.

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

2 years ago - By: Surrozen, Inc.

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

2 years ago - By: Surrozen, Inc.

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

2 years ago - By: Surrozen, Inc.

SURROZEN INC (SRZN) Stock News

SRZN Latest News, Press Relases and Analysis

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Q2 Profit on Gains

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conferences

SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024

SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024

SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024

SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023

SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023

This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

12 Health Care Stocks Moving In Friday's Pre-Market Session

Block upgraded, Bumble downgraded: Wall Street's top analyst calls

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023

SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023

SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Provides Corporate Update on Clinical Programs